TP53 and cancer: Alterations in p53 are amongst the most frequent in all human cancers and are associated with increased capacity to evade apoptosis leading to therapeutic resistance; consequently elucidating p53-independent DDR pathways that could overcome this resistance has been an intense area of research [1-4].